


Amended Claims (Attorney Docket No. LeA 34 813)

1. (Previously presented) Compounds of the general formula (I),



in which

- R^1 denotes hydrogen, C_1 - C_4 -alkyl, halogen, trifluoromethyl, trifluoromethoxy, cyano or nitro,
- R^2 denotes halogen, trifluoromethyl, trifluoromethoxy, cyano or nitro,
- R^3 denotes C_4 - C_7 -alkyl which may be substituted one or more times by fluorine or chlorine,
- R^4 denotes hydrogen or halogen, and
- A denotes oxygen.

2. (Original) Compounds according to Claim 1,

where

- R^1 denotes hydrogen, fluorine, chlorine, methyl, trifluoromethyl, trifluoromethoxy, cyano or nitro,
- R^2 denotes fluorine, trifluoromethyl, trifluoromethoxy, cyano or nitro,
- R^3 denotes n-butyl, n-pentyl, 4,4,4-trifluorobut-1-yl or 5,5,5-trifluoropent-1-yl,
- R^4 denotes hydrogen, and
- A denotes oxygen.

3. (Original) Compounds according to claim 1 or 2,

where

R^1 , R^2 , R^3 , R^4 and A have the meaning stated in claim 1 or 2, and

there is a hydrogen atom in position 4 of the phenyl ring substituted by R^1 and R^2 .

4. (Original) Compounds according to claim 1 or 2,

where R^1 , R^2 , R^3 , R^4 and A have the meaning stated in claim 1 or 2, and

R^1 and R^2 occupy positions 2 and 3 on the phenyl ring.


5. (Previously presented) Compounds according to Claim 1

where

R^1 , R^2 , R^3 , R^4 and A have the meaning stated in Claim 1, and


A is in position c of the benzene radical.

6. (Original) Process for preparing compounds according to Claim 1, characterized in that a compound of the general formula (II)



in which R^1 , R^2 , R^4 and A have the meaning stated in Claim 1,

is reacted in an inert solvent in the presence of a suitable base and, where appropriate, in the presence of a phase-transfer catalyst with a compound of the general formula (III)



in which

X^1 represents a suitable leaving group, and

R^3 has the abovementioned meaning.

7. (Cancelled).

8. (Cancelled).

9. (Previously presented) A pharmaceutical composition containing at least one of the compounds according to Claim 1 mixed with at least one pharmaceutically suitable essentially nontoxic carrier or excipient.

10. (Previously presented) A method of treating states of pain, comprising administering to a mammal an effective amount of a compound according to claim 1, wherein said pain is acute pain, chronic pain, cancer-induced pain, chronic neuropathic pain, diabetic neuropathy, neuralgia, peripheral nerve damage, central pain, trigeminal neuralgia, lumbago, back pain, or rheumatic pain.

11. (Previously presented) A method of treating Parkinson's disease, comprising administering to a mammal an effective amount of a compound according to claim 1.

12. (Currently amended) A method of treating states of neurodegenerative disorders, comprising administering to a mammal an effective amount of a compound according to claim 1, wherein said neurodegenerative disorder is cerebral vasospasm, cerebral ischaemias, craniocerebral trauma, migraine, spasticity, anoxia, hypoxia, ~~perinatal asphyxia~~, autoimmune diseases, ~~metabolic diseases~~, epilepsy, ~~brain disorders associated with atherosclerotic disease or arteriosclerotic disease~~, depression, Alzheimer's disease, ~~Parkinson's disease~~, Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, ~~multi-infarct dementia, or neurodegenerative disorders associated with bacterial and viral infections.~~